Investor Alert

Market Pulse Archives

Nov. 18, 2021, 6:27 a.m. EST

Coronavirus tally: Global cases of COVID-19 top 255 million and AstraZeneca says antibody treatment reduces risk of symptomatic illness

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

The global tally for the coronavirus-borne illness climbed above 255 million on Thursday, while the death toll edged above 5.12 million, according to data aggregated by Johns Hopkins University . The U.S. continues to lead the world with a total of 47.4 million cases and 767,435 deaths. The U.S. is still averaging more than 1,100 deaths a day, according to a New York Times tracker, although cases and hospitalizations are declining. Michigan and Minnesota are leading the nation by new cases on a per capital basis with caseloads up more than 60% in the last two weeks. AstraZeneca Plc /zigman2/quotes/200304487/composite AZN -1.78% /zigman2/quotes/203048482/delayed UK:AZN -1.02% said that Phase 3 trials of its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic COVID, Dow Jones Newswires reported. The pharmaceutical company said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths. India is second by cases after the U.S. at 34.5 million and has suffered 464,623 deaths. Brazil has second highest death toll at 611,851 and 21.9 million cases. In Europe, Russia has the most fatalities at 255,448 deaths, followed by the U.K. at 143,801.

US : U.S.: Nasdaq
$ 59.10
-1.07 -1.78%
Volume: 5.89M
Jan. 21, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$183.80 billion
Rev. per Employee
UK : U.K.: London
8,752.00 p
-90.00 -1.02%
Volume: 1.75M
Jan. 21, 2022 4:35p
P/E Ratio
Dividend Yield
Market Cap
£135.60 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.